Syed Samad, MD
Gastroenterology · Pine Bluff, ARNPI 1174585814
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,056 of the $4,652 with a category attached, or 65.7%. 19 manufacturers reported payments, led by Braintree Laboratories, Inc. at 31.2% of the total. Reporting peaked in 2021 at $1,265 and has fallen 96.0% since, to $51 in 2025.
Across 239 payments — averaging $19.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Braintree Laboratories, Inc.$1K
- AbbVie$635
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$475
- Medtronic$450
- Pfizer$351
- Johnson & Johnson$317
- plus $976 from 13 others
Across 2 payments — averaging $652.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1K
What the payments were for
- Food & beverage$3,05666%
- Education$4019%
- Gifts$1,17825%
- Entertainment$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Braintree Laboratories, Inc. | 67 | $1,449 |
| AbbVie(2 entities) | 33 | $635 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 30 | $475 |
| Medtronic(2 entities) | 16 | $450 |
| Pfizer | 21 | $351 |
| Johnson & Johnson | 10 | $317 |
| Redhill Biopharma Inc. | 17 | $273 |
| Ferring Pharmaceuticals Inc. | 13 | $164 |
| Axonics, Inc. | 6 | $119 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $69 |
| Intercept Pharmaceuticals, Inc. | 5 | $67 |
| Gilead | 4 | $59 |
| Merck | 3 | $56 |
| Mauna Kea Technologies, Inc. | 2 | $53 |
| Boston Scientific | 2 | $36 |
| Phathom Pharmaceuticals, Inc. | 2 | $28 |
| Ironwood Pharmaceuticals, Inc | 2 | $27 |
| Bristol Myers Squibb | 1 | $14 |
| Romark Laboratories, LC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$123
- SUPREP BOWEL PREP$107
- XIFAXAN$106
How this compares
$4,652 in reported general payments places this provider in the 55th percentile of 108 gastroenterology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 16 | $487,166 |
| LinzessLinaclotide | 180 | $124,621 |
| Humira PenAdalimumab | 12 | $85,152 |
| Budesonide ErBudesonide | 27 | $25,051 |
| IbsrelaTenapanor Hcl | 13 | $23,209 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 122 | $19,856 |
| CreonLipase/Protease/Amylase | 13 | $18,006 |
| Pantoprazole Sodium | 1,939 | $16,402 |
| MotegrityPrucalopride Succinate | 24 | $13,156 |
| Esomeprazole Magnesium | 187 | $5,960 |
| SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag | 47 | $5,876 |
| Mesalamine ErMesalamine | 41 | $5,852 |
| Sucralfate | 154 | $4,758 |
| Omeprazole | 340 | $4,684 |
| Mesalamine | 15 | $4,442 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $317 | $487,16616 claims |
| AbbVieLinzess, Creon | $635 | $142,628193 claims |
| Braintree Laboratories, Inc.Sutab, Suflave | $1,449 | $25,732169 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $69 | $13,15624 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 108 gastroenterology providers in Arkansas.
Other gastroenterology in Pine Bluff
- Ioannis PapayannisPine Bluff$6K
- Glenn DavisLittle Rock$2.7M
- Ranga BalasekaranSpringdale$235K
- Ali KhanLittle Rock$49K
- Jaymie PenningtonLittle Rock$17K
- Michael JohnsonLittle Rock$17K
- David BackstedtLittle Rock$16K
- Hrair SimonianFort Smith$15K
- Dhaval PatelLittle Rock$15K
- Jeffrey RobertsonLittle Rock$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.